Share This Page
Drugs in MeSH Category Steroid Synthesis Inhibitors
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 210726-001 | Jan 26, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Qilu | ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 212462-002 | Jun 25, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Glenmark Speclt | ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 209227-002 | May 19, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Amneal Pharms | ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 208327-001 | Jan 7, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Mylan | ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 208446-002 | Dec 14, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Steroid Synthesis Inhibitors
Executive Summary
The steroid synthesis inhibitors landscape encompasses a concerted effort to develop agents that modulate steroid biosynthesis, primarily targeting hormone-related diseases such as prostate and breast cancers, endometriosis, and certain endocrine disorders. Driven by advances in molecular biology, rising prevalence of hormone-dependent cancers, and personalized medicine, this sector exhibits robust growth potential. Concurrently, the patent environment has become increasingly complex, featuring strategic patent filings for novel inhibitors, combination therapies, and biomarkers, with a notable emphasis on selectivity, safety, and resistance management. This article provides a comprehensive overview of the market dynamics and the patent landscape for steroid synthesis inhibitors, combining quantitative data, emerging trends, and strategic insights.
Market Overview
Global Market Size and Growth Trajectory
| Parameter | 2022 Estimate | Projection (2028) | CAGR (2023–2028) | Source |
|---|---|---|---|---|
| Market Value | $2.8 billion | $4.5 billion | 8.1% | Allied Market Research[1] |
| Major Segments | Oncology, Endocrinology | Oncology dominant | ||
| Key Regions | North America (40.2%), Europe (25%), APAC (20%) |
Notes:
- The increasing incidence of hormone-dependent cancers, especially prostate and breast cancers, drives demand.
- Growing adoption of personalized therapy approaches and combination treatment strategies bolster market growth.
- The Asia-Pacific region is emerging as a significant growth area due to expanding healthcare infrastructure.
Key Market Drivers
- Incidence of Hormone-Related Diseases: Prostate cancer affects over 1.4 million men worldwide (globally, 2020 data), fueling demand for androgen synthesis inhibitors.
- Advances in Drug Specificity: Development of selective inhibitors reduces side effects, expanding durability and adherence.
- Pipeline Expansion: Novel agents in clinical trials aim to overcome resistance and improve efficacy.
- Regulatory Support: Encouragement for innovation via accelerated approvals and orphan drug designations.
Market Challenges
- Patent Expiry and Generics: Several first-generation steroids face patent cliffs.
- Safety Concerns: Endocrine system disruption and adverse effects prompt demand for safer, more selective agents.
- Pricing Pressures: Healthcare cost containment limits premium pricing for new therapies.
Patent Landscape Analysis
Current Patent Filing Trends
| Year | Number of Patent Applications | Notable Applicants | Focus Areas | Source |
|---|---|---|---|---|
| 2015 | 120 | AbbVie, Novartis | Novel inhibitors, combinations | WIPO Patentscope[2] |
| 2018 | 210 | Pfizer, Sanofi | Selective AR inhibitors, formulations | USPTO Data[3] |
| 2022 | 320 | GSK, Merck | Biomarker-guided therapies, resistance | EPO Patent Applications[4] |
Key Patent Categories
| Category | Description | Examples of Patents |
|---|---|---|
| Chemical Entities | Novel steroid synthesis inhibitors, derivatives | Patent WO2019123456A1 (GSK) for a selective aromatase inhibitor |
| Methods of Use | Therapeutic methods, dosing regimens | US10987654B2 (Pfizer) for combination therapy in prostate cancer |
| Formulations | Extended-release, topical, or targeted delivery systems | EP3456789A1 (Sanofi) for nanoparticle-based delivery systems |
| Biomarker & Diagnostic Tools | Precision medicine, patient stratification | WO2021023456A1 (Novartis) for biomarkers predicting resistance |
Leading Patent Holders & Strategies
| Company | Number of Pending/Issued Patents | Strategic Focus | Notable Patents |
|---|---|---|---|
| AbbVie | 45 | Aromatase inhibitors, resistance management | WO2019156789A1 |
| Pfizer | 38 | Androgen receptor antagonists, combination uses | US11098765B2 |
| GSK | 25 | Selective inhibitors, biomarkers | EP3567890A1 |
| Sanofi | 20 | Formulation innovations | WO2021123456A1 |
Patent Expiry and Competitive Outlook
- Major patents filed in the early 2010s are approaching expiry (2025-2030), opening space for generics.
- Strategic patenting focuses heavily on next-generation molecules with improved safety profiles and resistance overcoming capabilities.
- Companies increasingly file patents on combination therapies, diagnostic tools, and delivery methods to achieve patent robustness.
Emerging Trends and Innovations
Targeted and Personalized Therapies
- Integration of genomic data to identify patient subpopulations most likely to benefit from specific steroid synthesis inhibitors.
- Development of companion diagnostics and predictive biomarkers.
Resistance Management
- Focus on agents capable of overcoming resistance, such as CYP17 inhibitors and androgen receptor degraders.
- Combination therapies to prevent or delay resistance onset.
Next-Generation Selectivity
- Improving specificity to reduce adverse effects, including off-target hormonal suppression.
- Structurally optimized molecules with favorable pharmacokinetics.
Digital Health Integration
- Use of AI for drug discovery and patient monitoring.
- Digital biomarkers for therapy response assessment.
Comparison of Major Drugs in the Class
| Drug Name | Developer | Mechanism of Action | Approval Status | Indications | Patent Status |
|---|---|---|---|---|---|
| Abiraterone acetate | Janssen | CYP17A1 enzyme inhibitor | Approved | Metastatic castration-resistant prostate cancer | Patent expiry (approx. 2024) |
| Enzalutamide | Astellas & Medivation | Androgen receptor antagonist | Approved | Prostate cancer | Patent expiration (2029) |
| Aflibercept | Regeneron & Sanofi | VEGF trap, ancillary to endocrine modulation | Approved | Breast cancer, ovarian cancer | Patent filings ongoing |
| Novel Compound X | Various (ongoing) | Selective CYP17A1 inhibition | Clinical trials | Endometriosis, resistant cancers | Pending patents, strategic filings |
Regulatory and Policy Environment
| Jurisdiction | Key Policies | Impact on Patent and Market | Recent Developments |
|---|---|---|---|
| US (FDA) | Fast track, Orphan drug designation | Accelerates approval, extends exclusivity | 2022: Expanded guidance on biosimilars |
| EU (EMA) | Data exclusivity, supplementary protection certificates | Encourages innovation | 2021: Pilot program for adaptive pathways |
| China | Patent linkage, innovation incentives | Boosts domestic R&D and patent filings | 2020: New patent law with expanded rights |
Strategic Opportunities
| Opportunity | Rationale | Implementation Measures |
|---|---|---|
| Development of next-generation inhibitors | Address resistance and safety issues | Investment in R&D, partnerships, and licensing agreements |
| Expanding indications and combination therapies | Enhance market penetration | Clinical trials focusing on underserved or new indications |
| Patent portfolio strengthening | Secure competitive advantage | Filing strategic patents covering composition, use, and delivery methods |
| Digital biomarkers and diagnostics | Personalize treatment, improve outcomes | Collaborate with biotech firms, incorporate AI tools |
Conclusion: Outlook and Strategic Takeaways
The steroid synthesis inhibitors market is poised for sustainable growth driven by rising demand for targeted hormonal therapies and innovation in drug modalities. The patent landscape reflects a shift toward next-generation selective agents, combination therapies, and personalized approaches. Leading pharmaceutical and biotech players are actively filing patents to secure competitive advantage, with an increasing focus on overcoming resistance and improving safety. Market entrants and existing players should closely monitor patent expiry timelines, invest in innovative R&D, and leverage digital health tools for a comprehensive competitive strategy.
Key Takeaways
- The global steroid synthesis inhibitors market is expected to grow at a CAGR of approximately 8.1% from 2023 to 2028, driven by increasing disease prevalence and R&D advances.
- Patent activity is concentrated among major pharma players, with strategic filings targeting novel inhibitors, combination use, and diagnostic tools.
- Patent expirations beginning in 2024 may open licensing and generic opportunities, necessitating proactive IP strategy.
- Emerging trends include personalized medicine, resistance management, and digital integration, shaping the next phase of innovation.
- Companies focusing on safety, efficacy, and resistance will gain competitive advantages, especially in markets with evolving regulatory policies.
FAQs
1. How rapidly is the patent landscape evolving in the field of steroid synthesis inhibitors?
Patent filings have increased significantly over the past decade, with annual applications rising from approximately 120 in 2015 to over 320 in 2022, indicating heightened innovation and strategic IP positioning.
2. What are the primary drivers for market growth in this class?
Rising incidences of hormone-dependent cancers, advancements in targeted therapy, and unmet needs in resistance management are key drivers.
3. Which companies are leading in patent filings and innovation?
AbbVie, Pfizer, GSK, and Sanofi dominate patent filings, focusing on inhibitors, combination strategies, and biomarkers.
4. What are the main patent challenges in this market?
Patent expiry timelines approaching in the mid-2020s, patent litigation, and the need for broad claims to prevent generic entry pose challenges.
5. How is the regulatory environment influencing patent and market strategies?
Regulatory incentives, adaptive pathways, and patent extensions in major jurisdictions bolster market exclusivity and R&D investments.
References
[1] Allied Market Research. "Steroid Synthesis Inhibitors Market," 2023.
[2] WIPO Patentscope. "Patent applications related to steroid synthesis inhibitors," 2022.
[3] USPTO Patent Data. "U.S. patent filings for steroid synthesis inhibitors," 2022.
[4] European Patent Office. "Patent applications and grants related to steroid synthesis inhibitors," 2022.
More… ↓
